Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Annovera is a reusable, silicone-based contraceptive vaginal ring that contains two hormones—segesterone acetate (a progestin) and ethinyl estradiol (an estrogen). It is designed for female contraception and works primarily by suppressing ovulation. The ring is inserted into the vagina for 21 days, followed by a 7-day break, in repeated cycles for up to one year (13 cycles total). Annovera provides long-acting, patient-controlled birth control without requiring any procedures or device implantation. Its mechanism of action involves inhibition of ovulation through suppression of gonadotropins; it also causes changes in cervical mucus and endometrial lining to prevent sperm penetration and implantation[2][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on annovera.